Hipercolesterolemia em escolares e seus fatores de risco

OBJETIVO: Identificar os fatores de risco da hipercolesterolemia em escolares de sete a dez anos de idade. MÉTODOS: Estudo caso-controle, desenvolvido com 172 escolares do Município de Campinas, SP, pareados conforme sexo e trimestre de idade. Considerou-se caso a hipercolesterolemia, diagnosticada quando a criança apresentava colesterol ³200 mg/dL, e controle quando a criança apresentava colesterol entre 140 e 170 mg/dL. Além da coleta de sangue para a dosagem do nível de colesterol, foram levantados dados sobre pressão arterial, índice de massa corporal e história familiar de doenças cardiovasculares. Os dados foram analisados por correlação bivariada usando o teste t para as variáveis quantitativas e o qui-quadrado para a história familiar de doenças cardiovasculares. O odds-ratio foi usado para estimar o risco de hipercolesterolemia. RESULTADOS: A média do colesterol encontrada foi de 215 mg/dL nos casos e de 154 mg/dL nos controles. A média da pressão arterial sistólica foi de 107 mmHg nos casos e de 106 mmHg nos controles e da diastólica foi de 67 mmHg nos casos e 68 mmHg nos controles. O índice de massa corporal (Kg/m²) apresentou média de 18,2 nos casos e de 17,1 nos controles. A análise bivariada mostrou associação entre hipercolesterolemia e índice de massa corporal (p=0,048). O odds ratio apontou a obesidade como fator de risco para a hipercolesterolemia (OR=2,17; IC=1,05 a 4,45). CONCLUSÕES: Os resultados apontaram a obesidade como fator de risco da hipercolesterolemia.

Estudo Comparativo, Aleatorizado, em Dupla Ocultação, de Orlistat Versus Placebo, de Eficácia e Segurança, em Doentes Obesos com Hipercolesterolemia Ligeira a Moderada

INTRODUCTION: Obesity is a chronic disease and a serious health problem that leads to increased prevalence of diabetes, hypertension, dyslipidemia and gallbladder disease. OBJECTIVE: To evaluate the efficacy of orlistat for weight loss and improved lipid profile compared to placebo in obese patients with hypercholesterolemia, treated over a period of 6 months. METHODOLOGY: In a 6-month, multicenter (10 centers in Portugal), double-blind, parallel, placebo-controlled study, 166 patients, aged 18-65 years, body mass index (BMI) > or = 27 kg/m2, LDL cholesterol > 155 mg/dl, were randomized to a reduced calorie diet (600 kcal/day deficit) plus orlistat three times a day or placebo. Exclusion criteria included triglycerides > 400 mg/dl, severe cardiovascular disease, uncontrolled hypertension, type 1 or 2 diabetes under pharmacological treatment, and gastrointestinal or pancreatic disease. RESULTS: The mean difference in weight from baseline was 5.9% (5.6 kg) in the orlistat group vs. 2.3% (2.2 kg) in the placebo group. In the orlistat group 49% of patients achieved 5-10% weight loss and 8.8% achieved > 10%. The orlistat group showed a significant reduction in total and LDL cholesterol, with similar changes for HDL in both treatment groups. The frequency of gastrointestinal adverse events was slightly higher in the orlistat group than in the placebo group, leading to discontinuation in 7 patients. CONCLUSION: Treatment with orlistat plus a reduced calorie diet for 6 months achieved significant reductions in weight, BMI and lipid parameters.

Efeito da berinjela sobre os lípides plasmáticos, a peroxidação lipídica e a reversão da disfunção endotelial na hipercolesterolemia experimental

OBJETIVO: Estudar o efeito do suco da berinjela sobre os lípides plasmáticos, o colesterol tecidual, a peroxidação lipídica das LDL nativas, oxidadas e da parede arterial e o relaxamento dependente do endotélio, em coelhos hipercolesterolêmicos. MÉTODOS: Coelhos foram separados em grupos controle (GC), hipercolesterolêmico (GH) e berinjela (GB), (n=10). Os animais do GC foram alimentados com ração normal, o GH e o GB com ração acrescentada de colesterol (0,5%) e gordura de babaçu (10%) durante 30 dias. Ao GB acrescentou-se suco de berinjela, nos últimos 15 dias do experimento. Os lípides plasmáticos foram medidos através de kits enzimáticos, a peroxidação lipídica pela dosagem do malondialdeído (MDA) e o relaxamento dependente do endotélio, por curvas de concentração efeito pela acetilcolina e nitroprussiato. RESULTADOS: O peso dos animais foi menor no GB em relação ao GC e GH (p<0,05). O colesterol total plasmático, as LDL e os triglicérides que se elevaram no GH, reduziram-se em 19%, 29% e 38%, respectivamente no GB (p<0,05). O colesterol tecidual foi menor no GB (50%) em relação ao GH (p<0,05). Nos animais do GB ocorreu redução significante do teor de MDA nas LDL nativas (56%) e oxidadas (22%), assim como na parede arterial (30%) (p<0,05). O relaxamento máximo dependente do endotélio, , elevou-se significantemente em 28% no GB em relação ao GH (p<0,05). CONCLUSÃO: O suco de berinjela administrado a coelhos hipercolesterolêmicos reduziu significantemente o peso corpóreo, o colesterol total, as LDL plasmáticas, os triglicérides, o colesterol tecidual, a peroxidação lipídica das LDL nativas, oxidadas e da parede arterial, assim como aumentou o relaxamento dependente do endotélio.

Avaliação de um questionário simplificado de freqüência de consumo alimentar como preditor de hipercolesterolemia em adolescentes

OBJETIVO: Avaliar se um questionário simplificado desenvolvido para avaliação de consumo de gordura prediz as concentrações de colesterol total sérico (CTs) obtidas em adolescentes. MÉTODOS: De uma amostra probabilística de 28 turmas da 5ª série ao 3º ano das escolas estaduais de Niterói, RJ, 577 jovens participaram da coleta de sangue (23,7% de não-resposta) e 539 responderam ao questionário de freqüência de consumo alimentar com nove itens. Avaliaram-se a consistência interna do questionário através do alpha de Cronbach e a concordância entre os teores de CTs e consumo alimentar pelo Kappa ponderado (Kw). RESULTADOS: O valor do Kw foi muito baixo (< -0,05), apesar da boa consistência interna do questionário (alpha de Cronbach > 0,66). CONCLUSÃO: Os resultados apontam que o questionário simplificado não foi preditor das concentrações de CTs nos jovens.

Avaliação dos níveis séricos de homocisteína em transplantados renais com e sem hipercolesterolemia

FUNDAMENTO: A ocorrência de hiper-homocisteinemia parece ser freqüente após o transplante renal. Nenhum estudo até o momento avaliou o papel da homocisteína (Hcy) associada à dislipidemia no Brasil. OBJETIVO: Determinar a prevalência de hiper-homocisteinemia (Hcy sérica >15 mmol/l) em pacientes estáveis submetidos a transplante renal e avaliar o papel dos lipídios séricos e da função do enxerto nos níveis de Hcy sérica. MÉTODOS: Cento e cinco pacientes estáveis submetidos a transplante renal foram avaliados, levando-se em consideração idade, tempo pós-transplante, níveis séricos de colesterol, função do enxerto, proteinúria e uso de ciclosporina (analisados por regressão linear múltipla). A prevalência de hiper-homocisteinemia foi de 74,3%. Os pacientes foram divididos em dois grupos: hipercolesterolêmicos (colesterol total > 200 mg/dl, colesterol LDL > 130 mg/dl) e normocolesterolêmicos. RESULTADOS: Os pacientes hipercolesterolêmicos eram mais velhos, tinham menor tempo pós-transplante, menor depuração de creatinina endógena, maior proteinúria e níveis séricos mais elevados de Hcy. Os pacientes com hiper-homocisteinemia tinham níveis séricos de triglicérides significativamente mais elevados e função do enxerto significativamente pior; além disso, seus níveis de colesterol LDL apresentaram tendência a ser mais elevados. Houve uma correlação positiva entre os níveis séricos de creatinina e de Hcy (r = 0,32; p = 0,01). A análise de regressão linear múltipla revelou que tanto a dislipidemia quanto a função renal afetam de forma independente os valores de Hcy. CONCLUSÃO: Observamos uma alta prevalência de hiper-homocisteinemia em pacientes submetidos a transplante renal, especialmente em hipercolesterolêmicos, sugerindo que uma pior função do enxerto pode influenciar negativamente os níveis séricos de Hcy e colesterol. Estudos futuros deverão investigar se esse perfil metabólico adverso está associado com maior mortalidade cardiovascular no longo prazo.

Relación de la ingesta de grasas saturadas y los factores de riesgo coronario (obesidad, hipertensión, hipercolesterolemia) en personas mayores de 60 años de una clínica privada de Monterrey, N.L.

Tesis (Maestría en Salud Pública) UANL

Riesgo dietético aterogénico y presencia de hipercolesterolemia y obesidad en la población rural mayor de diez años de edad, Nuevo León, México, 1990

Tesis (Maestría en Salud Pública con Especialidad en Nutrición Comunitaria) UANL.

Relación de la ingesta de grasas saturadas y los factores de riesgo coronario (Hipertensión, Hipercolesterolemia y Obesidad) en personas mayores de 60 años de una clínica privada de la ciudad de Monterrey,N.L.

Tesis (Maestría en Salud Pública con Especialidad en Nutrición Comunitaria) UANL.

Avaliação do colesterol plasmático em coelhos com hipercolesterolemia induzida e tratados com extrato etanólico de própolis

The propolis (bee glue) is a product rich in flavonoids, which are known for antioxidant activities, a protective action to the lipoproteins LDL-cholesterol against lipid peroxidation. Because they have antioxidant properties, we investigated the effect of the ethanolic extract propolis on the plasma level of cholesterol in rabbits (Oryctolagus cuniculus) submitted to hypercholesterolaemia. The animals were divided into 4 groups. G 1=received commercial feed and water, G 2=received enriched feed and water, G 3=received enriched feed and ethanol, G 4=received enriched feed and ethanolic extract of propolis. The hypercholesterolaemia was induced with commercial feed enriched with egg yolk. The animals received the ethanolic extract propolis at the concentration of 100 mg/kg daily. Weekly, after fast of 14 hours, the samples of blood were collected from the marginal vein of the ear. The plasma was used for the estimation total cholesterol. From the results obtained, we verified that the ethanolic extract propolis significantly reduced the plasma level cholesterol (109,59 mg/dL, p<0,05), compared to the animals treated with ethanol (331,38 mg/dL), and also to those receiving the commercial feed only, with cholesterol at 269,74 mg/dL.

Eficácia e segurança da atorvastatina no tratamento de pacientes com hipercolesterolemia primária

Introduction: Hypercholesterolemia is an important risk factor for cardiovascular disease, the first cause of death and third reason for hospital admissions in Brazil. The reduction of serum cholesterol levels reduces morbidity and mortality from cardiovascular disease. The present study evaluated the efficacy and safety of atorvastatin in the treatment of Brazilian patients with primary hypercholesterolemia (types IIA and IIB dyslipidemias). Patients and methods: After a 4-week wash-out period, 152 patients were treated with atorvastatin at the initial dose of 10 mg/day. According to treatment efficacy within the first 8 weeks this dose could be increased to 20 mg/day. Treatment lasted for a total of 16 weeks, and its efficacy was evaluated by the reduction of serum levels of LDL-cholesterol, total cholesterol, HDL-cholesterol, and triglycerides, as well as by the propotion of patients that achieved the target levels recommended by the National Cholesterol Education Program - Adult Treatment Panel II (NCEP ATP II) Results: The analysis of efficacy was conducted in 145 patients. Atorvastatin led to significant reductions in the levels of LDL-cholesterol after 8 and 16 weeks of treatment (P<0.001 for both comparisons). The relative reduction of such levels was 38% (P<0.001 after 8 and 16 weeks). Atorvastatin also led to significant reductions of total cholesterol and triglycerides. At the end of the study, 81% of patients achieved the target LDL-cholesterol levels recommended by NCEP ATP II. Treatment was well tolerated, and was interrupted due to creatine phosphokinase elevation in only one patient. Conclusion: Atorvastatina is efficacious and safe in the treatment of patients with primary hypercholesteromia. © Copyright Moreira Jr. Editora. Todos os direitos reservados.

Avaliação do efeito do alho (Allium sativum L.) sobre o colesterol plasmático em coelhos com hipercolesterolemia induzida

The use of plants to treat diseases or even to cure them is a high diffused popular tradition, and several studies discuss the therapeutic and pharmacological properties of garlic in the reduction of hyperlipidaemias. The objective of the present study was to investigate the influence of the aqueous extract of garlic (Allium sativum) to treat the serum cholesterol of rabbits with experimental hypercholesterolemia. The animals were divided into G1 (control group) and G2 (group treated with garlic). The experiment was developed according to 3 phases: during the 1st phase, all animals were provided with a regular diet to evaluate the basal cholesterol; during the 2nd phase, all animals received a supplemented diet until the end of the experiment, in order to develop hypercholesterolemia and, in the 3rd phase, the animals on G2 received the garlic treatment. The cholesterol registered on the 1st phase was 39.94 ± 9.57 mg dL-1. On the 2nd phase, there was an increase on the serum cholesterol level in both groups - higher than 100 mg dL-1. Concerning the treatment, the garlic did not reduce the serum cholesterol in rabbits.

Avaliação dos efeitos do alho (Allium sativum L.) sobre o colesterol plasmático em coelhos com hipercolesterolemia induzida

The use of plants in treatments of diseases or even in the cure of them is a high difused popular tradition, and several works talk about the therapeutic and pharmacological properties of garlic in the reduction of hyperlipidaemias. The objective of the present work was to investigate the influence of garlic (Allium sativum) aqueous extract treatment on the serum cholesterol of rabbits in experimental hypercholesterolemia. The animals were divided in G1 (control group) and G2 (group with garlic treatment). The experiment was developed in 3 phases: during the 1st phase, all the animals received regular diet for evaluation of basal cholesterol; in the 2nd phase all the animals received supplemented diet until the end of the experiment, in order to develop hypercholesterolemia and in the 3rd phase, the animals of G2 received the garlic treatment. The cholesterol registered on the 1st phase was 39,94 ± 9,57mg/dL. On the 2nd phase, there was an increase on the serum cholesterol level in both groups – higher than 100mg/dL. Concerning the treatment, garlic didn’t reduce the serum cholesterol in rabbits

Avaliação dos efeitos do cogumelo do sol (Agaricus blazei) sobre o colesterol plasmático em coelhos com hipercolesterolemia induzida

Prophylactic or therapeutic treatments administered with medicinal plants and natural products are used in popular medicine of diverse people since prehistoric times to the present days. Species with medicinal properties are increasingly studied in an attempt to understand their possible effects on organisms and their functioning. This study aimed to analyze the effect of the mushroom Agaricus blazei (aqueous extract) in rabbits subjected to experimental hypercholesterolemia. The animals were divided into two groups (control and treated with the mushroom) whose experimental protocol was divided into three phases: Phase 1, the animals were fed a normal diet to evaluate the physiological level of cholesterol; phase 2, the animals were fed a supplemented diet to induce hypercholesterolemia and in phase 3, the animals of control group continued to take high-cholesterol diet and the animals of treated group high-cholesterol diet including treatment with the mushroom. Weekly, after fasting of 14 hours, blood samples were collected from the animals and its plasma was stored for later measurement of plasmatic cholesterol. In the first phase, the cholesterol level was, on average, 31,30  7,34 mgdL-1. In the second phase, there was a significant increase (p<0,05) in cholesterol level of both groups. During the last phase of the experiment, the mushrooms didn’t cause reduction in plasmatic cholesterol of treated rabbits, however, prevent disease progression, maintaining the cholesterol level established at the beginning of treatment, whereas, in the control group, total serum cholesterol increased significantly at this stage